FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2325689095> ?p ?o ?g. }

• W2325689095 abstract "Objective: We evaluated whether antibody response against Epstein-Barr virus (EBV), cytomegalovirus (CMV), and herpes simplex virus 1 and 2 (HSV) are associated with relapse rate in pediatric patients with multiple sclerosis (MS). Background Elevated EBV titers have been shown to be associated with having MS. Data conflict as to whether EBV response predicts disease activity or disease subtype. It is not known if viral antibody levels are associated with relapse rate. Design/Methods: Sera were collected early during disease course in patients who subsequently received prospective clinical follow-up to document relapses at 6 pediatric MS clinics. Antibodies against EBV early antigen (EBVEA, a marker of viral reactivation), Epstein-Barr nuclear antigen-1 (EBNA1), HSV, and CMV were measured by ELISA. A repeated events analysis was employed to determine if viral antibody response or status (positive vs. negative) predicted subsequent relapses. Proportional hazards models adjusted for the time-varying covariate of disease-modifying therapy usage and fixed demographic variables. Results: 111 participants had serum from initial visit and subsequent relapse data. The prevalence of positive status for EBVEA, EBNA1, CMV, HSV1, and HSV2 were, respectively, 44.1%, 89.2%, 24.3%, 38.7%, and 21.6%. There was no statistically significant association in the relapse hazard rate for EBVEA (hazard ratio (HR) 0.97, 95%CI:0.78 to 1.22, p=0.81) or for EBNA1 antibody response (HR 1.08, 95%CI: 0.71 to 1.65, p=0.7). Adjustment for disease-modifying therapy, race, ethnicity, gender and HLA-DRB1 status did not substantially affect HRs. Similarly, HRs for EBV status, CMV titer or status and HSV-1 or 2 titers or status, did not show an association with subsequent relapse rate. Conclusions: Although previous studies have shown an association between prior infection with EBV and risk of MS, we did not detect an association between EBV, CMV or HSV antibody response and subsequent relapse rate in pediatric MS patients. Supported by: Dr. Graves is supported by the National Multiple Sclerosis Society Sylvia Lawry Award. The work was funded by the Nancy Davis Foundation and the NMSS. Disclosure: Dr. Graves has nothing to disclose. Dr. Krupp has received personal compensation for activities with Teva Neuroscience, BiogenIdec, Serono, Inc., Bayer Pharmaceuticals Corporation, Guidepoint Global, Pfizer Inc, Axon Advisors, Sanofi-Aventis Pharmaceuticals, Inc., as a speaker, consultant and/or participant on an advisory board. Dr. Krupp has received (royalty or license fee or contractual rights) payments from Genzyme Corporation, Bristol-Myers Squibb Company, MedImmune, and Novartis. Dr. Krupp has received research support from Serono Inc. and Biogen Idec. Dr. Weinstock-Guttman has received personal compensation for activities with Acorda Therapeutics, Biogen Idec, Serono, Inc., Novartis, Pfizer Inc, Teva Neuroscience as a speaker and/or participant on an advisory board. Dr. Weinstock-Guttman has received research support from Acorda Therapeutics, Biogen Idec, Serono Inc., Novartis, Pfizer Inc, Teva Neuroscience, National Multiple Sclerosis Society, the National Institutes of Health, ITN, Teva Neuroscience, Aspreva-Roche, Acorda Therapeutics and Shire Pharmaceuticals. Dr. Strober has nothing to disclose. Dr. Belman has nothing to disclose. Dr. Yeh has nothing to disclose. Dr. Ness has received research support from EMD Serono. Dr. Gorman has nothing to disclose. Dr. Rodriguez has nothing to disclose. Dr. Chitnis has received personal compensation for activities with Teva Neuroscience, Biogen Idec, Sanofi-Aventis Pharmaceuticals, Inc., and Novartis. Dr. Chitnis has received research support from Merck Serono. Dr. Waubant has received personal compensation for activities with Teva Neuroscience, Actelion, Sanofi-Aventis Pharmaceuticals, Roche Diagnostics Corporation and Biogen Idec as a speaker and/or consultant. Dr. Waubant has received research support from Biogen Idec and Sanofi-Aventis Pharmaceuticals." @default.
• W2325689095 created "2016-06-24" @default.
• W2325689095 creator A5000331361 @default.
• W2325689095 creator A5016970306 @default.
• W2325689095 creator A5017405490 @default.
• W2325689095 creator A5035792887 @default.
• W2325689095 creator A5037404899 @default.
• W2325689095 creator A5051333420 @default.
• W2325689095 creator A5052262813 @default.
• W2325689095 creator A5055725062 @default.
• W2325689095 creator A5068541928 @default.
• W2325689095 creator A5075596287 @default.
• W2325689095 creator A5085186797 @default.
• W2325689095 date "2012-04-22" @default.
• W2325689095 modified "2023-10-17" @default.
• W2325689095 title "EBV, CMV, and HSV IgG Titers Are Not Predictive of Subsequent Relapse Risk in Pediatric Multiple Sclerosis (P02.096)" @default.
• W2325689095 doi "https://doi.org/10.1212/wnl.78.1_meetingabstracts.p02.096" @default.
• W2325689095 hasPublicationYear "2012" @default.
• W2325689095 type Work @default.
• W2325689095 sameAs 2325689095 @default.
• W2325689095 citedByCount "0" @default.
• W2325689095 crossrefType "journal-article" @default.
• W2325689095 hasAuthorship W2325689095A5000331361 @default.
• W2325689095 hasAuthorship W2325689095A5016970306 @default.
• W2325689095 hasAuthorship W2325689095A5017405490 @default.
• W2325689095 hasAuthorship W2325689095A5035792887 @default.
• W2325689095 hasAuthorship W2325689095A5037404899 @default.
• W2325689095 hasAuthorship W2325689095A5051333420 @default.
• W2325689095 hasAuthorship W2325689095A5052262813 @default.
• W2325689095 hasAuthorship W2325689095A5055725062 @default.
• W2325689095 hasAuthorship W2325689095A5068541928 @default.
• W2325689095 hasAuthorship W2325689095A5075596287 @default.
• W2325689095 hasAuthorship W2325689095A5085186797 @default.
• W2325689095 hasConcept C126322002 @default.
• W2325689095 hasConcept C147483822 @default.
• W2325689095 hasConcept C159654299 @default.
• W2325689095 hasConcept C203014093 @default.
• W2325689095 hasConcept C207103383 @default.
• W2325689095 hasConcept C2522874641 @default.
• W2325689095 hasConcept C2776409557 @default.
• W2325689095 hasConcept C2777732132 @default.
• W2325689095 hasConcept C2779134260 @default.
• W2325689095 hasConcept C2780640218 @default.
• W2325689095 hasConcept C2780727368 @default.
• W2325689095 hasConcept C2781196997 @default.
• W2325689095 hasConcept C2781375147 @default.
• W2325689095 hasConcept C32611913 @default.
• W2325689095 hasConcept C44249647 @default.
• W2325689095 hasConcept C71924100 @default.
• W2325689095 hasConceptScore W2325689095C126322002 @default.
• W2325689095 hasConceptScore W2325689095C147483822 @default.
• W2325689095 hasConceptScore W2325689095C159654299 @default.
• W2325689095 hasConceptScore W2325689095C203014093 @default.
• W2325689095 hasConceptScore W2325689095C207103383 @default.
• W2325689095 hasConceptScore W2325689095C2522874641 @default.
• W2325689095 hasConceptScore W2325689095C2776409557 @default.
• W2325689095 hasConceptScore W2325689095C2777732132 @default.
• W2325689095 hasConceptScore W2325689095C2779134260 @default.
• W2325689095 hasConceptScore W2325689095C2780640218 @default.
• W2325689095 hasConceptScore W2325689095C2780727368 @default.
• W2325689095 hasConceptScore W2325689095C2781196997 @default.
• W2325689095 hasConceptScore W2325689095C2781375147 @default.
• W2325689095 hasConceptScore W2325689095C32611913 @default.
• W2325689095 hasConceptScore W2325689095C44249647 @default.
• W2325689095 hasConceptScore W2325689095C71924100 @default.
• W2325689095 hasLocation W23256890951 @default.
• W2325689095 hasOpenAccess W2325689095 @default.
• W2325689095 hasPrimaryLocation W23256890951 @default.
• W2325689095 hasRelatedWork W1427736029 @default.
• W2325689095 hasRelatedWork W1489811431 @default.
• W2325689095 hasRelatedWork W1516922859 @default.
• W2325689095 hasRelatedWork W1570753083 @default.
• W2325689095 hasRelatedWork W1626138348 @default.
• W2325689095 hasRelatedWork W1697477849 @default.
• W2325689095 hasRelatedWork W2076561131 @default.
• W2325689095 hasRelatedWork W2172569637 @default.
• W2325689095 hasRelatedWork W2241143333 @default.
• W2325689095 hasRelatedWork W2303917887 @default.
• W2325689095 hasRelatedWork W2415726952 @default.
• W2325689095 hasRelatedWork W2561872743 @default.
• W2325689095 hasRelatedWork W2562732905 @default.
• W2325689095 hasRelatedWork W2590340538 @default.
• W2325689095 hasRelatedWork W2615311368 @default.
• W2325689095 hasRelatedWork W2749646834 @default.
• W2325689095 hasRelatedWork W631190283 @default.
• W2325689095 hasRelatedWork W81560786 @default.
• W2325689095 hasRelatedWork W860202733 @default.
• W2325689095 hasRelatedWork W136591520 @default.
• W2325689095 isParatext "false" @default.
• W2325689095 isRetracted "false" @default.
• W2325689095 magId "2325689095" @default.
• W2325689095 workType "article" @default.